| 翻訳と辞書 |
Insulin lispro
Insulin lispro (marketed by Eli Lilly and Company as "Humalog") is a fast acting insulin analog. It was first approved for use in the United States in 1996, making it the first insulin analog to enter the market.〔(【引用サイトリンク】url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020563&DrugName=HUMALOG&ActiveIngred=INSULIN%20LISPRO%20RECOMBINANT&SponsorApplicant=LILLY&ProductMktStatus=1&goto=Search.DrugDetails )〕
Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for postprandial injections.〔(【引用サイトリンク】title=Insulin Lispro: A Fast-Acting Insulin Analog )〕
Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a longer acting insulin (e.g. Insulin degludec) for good glycemic control.
==Medical uses==
Insulin lispro is an FDA approved drug used to treat people living with Type 1 diabetes or Type 2 diabetes.〔Product Information: HUMALOG(R) pen injection, insulin lispro (rDNA origin) pen injection. Eli Lilly and Company, Indianapolis, IN, 2007〕 Insulin lispro has non-FDA labeled uses for diabetic nephropathy prevention, diabetic neuropathy prevention, and cardiovascular disease prevention.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Insulin lispro」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|